Evolution of Ferment conference to kick off Summer 2025BOSTON, Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters.Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference SeriesEach Ferment in the 2025 series will dive deep into specific focus areas—spanning Ginkgo's cell engineering and biosecurity offerings—and highlight how Ginkgo's broad horizontal platform for engineering biology is enabling transformative solutions across markets including pharma & biotech, agriculture, industrial biotech, government, and beyond. Speawkers and panelists will include Ginkgo experts, partners, and industry leaders who are applying engineered biology to discover, optimize, and manufacture cutting-edge products.Attendees will also get a close look at Ginkgo's technologies and the innovations they have delivered to partners around the world. In addition, entirely new products and next-generation services will be showcased, including Ginkgo Datapoints' high-throughput AI-driven data generation services; Ginkgo Automation's Reconfigurable Automation Cart (RAC) systems; and Ginkgo Biosecurity's product suite anchored by Canopy (persistent, environmental pathogen monitoring) and Horizon (data-driven global threat intelligence)."We made big changes in 2024, and our mission is stronger than ever," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "Whether you're seeking the perfect antibody, looking to spin up a data generation engine to train your biological AI model, outfitting your lab with extensible and flexible automation, or building a new biosecurity solution to meet your mission's demands, you can find your needle in our tech stack

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRCBOSTON, Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bioenergy Research Center at the University of Wisconsin–Madison. This new system is designed to support the diverse needs of multiple investigators and research teams simultaneously, enabling GLBRC scientists to more efficiently discover and optimize synthesis of biofuels and bioproducts from plant biomass

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeuticsBOSTON, Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.iPSC-derived cell therapies have the potential to transform cancer care by offering scalable, 'off-the-shelf' treatment options. However, bringing efficacious therapies to patients requires robust design and screening processes to improve persistence in the patient to enable durable clinical responses. By combining Universal Cells' proprietary iPSC-derived cell technologies with Ginkgo's expertise in design and screening large CAR libraries and its high throughput, multimodal immune cell engineering platform, the companies aim to accelerate the development of more potent and durable cell therapies while maintaining manufacturability at scale.Ginkgo's approach leverages computational tools, deep expertise in library assembly and screening, and rigorous statistical analysis and biological insight to help partners discover and engineer optimal therapeutic designs with greater speed and precision. Ginkgo's platform capabilities extend across multiple dimensions of cell therapy development, including chimeric antigen receptor (CAR) discovery and optimization, armoring strategies for enhanced cell survival and persistence, and gene editing tools for immune cell engineering